New antibody drug takes on advanced tumors in first human trial
NCT ID NCT05143970
First seen Mar 27, 2026 · Last updated Jun 19, 2026 · Updated 15 times
Summary
This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe dose. In the second part, it is combined with chemotherapy and trastuzumab for HER2-positive breast cancer patients. The goal is to check safety and find the right dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPH5301 (an experimental antibody targeting CD73), given alone or with chemotherapy (paclitaxel) and trastuzumab
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers, especially HER2-expressing breast cancer, by helping the immune system fight tumors.
What could go wrong
This is a very early phase 1 trial with only 27 participants, so safety and dosing are still being figured out. The drug may not work or could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.